Cancer Chemother Pharmacol
-
Publication Venue For
-
Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers..
89:413-422.
2022
-
Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors..
85:173-183.
2020
-
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)..
84:909-917.
2019
-
The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors..
84:383-392.
2019
-
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer..
83:717-726.
2019
-
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors..
82:493-503.
2018
-
CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine..
81:365-372.
2018
-
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors..
81:355-364.
2018
-
Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy..
80:421-431.
2017
-
Phase I study of pazopanib plus TH-302 in advanced solid tumors..
79:611-619.
2017
-
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer..
78:577-584.
2016
-
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer..
75:993-1004.
2015
-
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)..
75:729-737.
2015
-
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study..
75:851-859.
2015
-
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors..
75:343-352.
2015
-
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)..
74:927-938.
2014
-
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors..
74:867-874.
2014
-
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer..
73:991-997.
2014
-
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma..
72:1305-1314.
2013
-
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer..
71:883-892.
2013
-
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors..
70:251-258.
2012
-
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors..
70:95-102.
2012
-
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients..
69:1507-1518.
2012
-
The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients..
69:1189-1196.
2012
-
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis..
69:425-430.
2012
-
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial..
68:1431-1438.
2011
-
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors..
68:1377-1385.
2011
-
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer..
68:1291-1304.
2011
-
BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors..
67:855-865.
2011
-
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination..
67:503-509.
2011
-
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)..
67:465-474.
2011
-
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors..
67:455-463.
2011
-
Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93)..
66:1013-1017.
2010
-
A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer..
65:557-561.
2010
-
A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells..
64:1053-1058.
2009
-
BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line..
63:753-758.
2009
-
Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma..
63:517-524.
2009
-
Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors..
63:219-228.
2009
-
A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
2019